Dec. 20, 2024
| Today’s news and insights for biopharma leaders
|
NOTE FROM THE EDITOR
BioPharma Dive won't be publishing over the next two weeks as we break for the holidays. But keep an eye out for a few special newsletters on Dec. 23, Dec. 27, and Dec. 30, featuring some of the year's top stories and trends, as well as a unique look at investment and dealmaking totals.
We'll be back on Jan. 2 with our usual news and analysis, along with a primer on upcoming clinical trial results you won't want to miss. In the meantime, happy holidays and as always, thanks for reading BioPharma Dive.
|
UPDATED
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.
|
News roundup
The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to leave the agency, and two biotechs cut research deals.
|
Even with another mid-stage setback, Roche believes there were enough positive signs to “merit further exploration” of the drug, which it’s been developing with Prothena for more than a decade.
|
An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare conditon.
|
UPDATED
With the funding of two startups this week, OrbiMed has passed Alexandria Venture Investments to become the third most active biotech investor since 2022, according to BioPharma Dive data.
|
|
What is the key to an anti-obesity drug achieving sustainable weight loss? Learn how sponsors can optimize clinical trial execution to differentiate their obesity pipeline early on in this playbook.
|
|
From Our Library
Playbook
Custom content for Avant Healthcare
|
Webinar - on demand
Custom content for Univar Solutions
|
Trendline
Supported by PHCbi
|
| 
